The FDA designated fast-track status to Nordic Nanovector's Phase IIb Betalutin, or 177Lu-lilotomab satetraxetan, being developed to treat patients with relapsed or refractory follicular lymphoma after two or more prior systemic therapies.
Nordic's follicular lymphoma drug nabs FDA fast-track status
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.